Drugs / Mocertatug rezetecan
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06431594 | Jul 2024 → Sep 2027 expected | neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07694427 | Oct 2026 → Sep 2029 expected | ovarian neoplasm | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07684612 | Sep 2026 → May 2030 expected | ovarian neoplasm | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07286266 | Jun 2026 → Dec 2029 expected | ovarian neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT07286331 | Jun 2026 → Feb 2028 expected | endometrial cancer | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mocertatug rezetecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07286266 ↗ |
| Known as | Mo-Rez | “This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care.” NCT07286331 ↗3“mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer” NCT07684612 ↗ “This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer” NCT07286266 ↗ “mocertatug rezetecan (Mo-Rez) alone or in combination with bevacizumab” NCT07694427 ↗ |